Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Spero Therapeutics (SPRO) Return on Capital Employed (2017 - 2025)

Spero Therapeutics (SPRO) has disclosed Return on Capital Employed for 9 consecutive years, with 1.04% as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Return on Capital Employed fell 103.0% year-over-year to 1.04%, compared with a TTM value of 1.04% through Sep 2025, down 103.0%, and an annual FY2024 reading of 0.75%, down 94.0% over the prior year.
  • Return on Capital Employed was 1.04% for Q3 2025 at Spero Therapeutics, up from 1.05% in the prior quarter.
  • Across five years, Return on Capital Employed topped out at 0.21% in Q4 2023 and bottomed at 2.0% in Q3 2022.
  • Average Return on Capital Employed over 5 years is 0.62%, with a median of 0.64% recorded in 2022.
  • The sharpest move saw Return on Capital Employed plummeted -131bps in 2022, then soared 191bps in 2023.
  • Year by year, Return on Capital Employed stood at 0.63% in 2021, then dropped by -1bps to 0.64% in 2022, then surged by 133bps to 0.21% in 2023, then plummeted by -577bps to 0.99% in 2024, then fell by -5bps to 1.04% in 2025.
  • Business Quant data shows Return on Capital Employed for SPRO at 1.04% in Q3 2025, 1.05% in Q2 2025, and 1.14% in Q1 2025.